Literature DB >> 29684111

The Impact of Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use Among Older Adults.

Danijela Gnjidic1, George O Agogo2, Christine M Ramsey2,3, Daniela C Moga4,5,6, Heather Allore2,7.   

Abstract

Background: Use of potentially inappropriate medications (PIM) among people with dementia is common. We assessed the patterns of medication use from 1-year before dementia diagnosis, to 1-year after dementia diagnosis, compared with patterns of medication use in people without dementia.
Methods: We conducted longitudinal study using the National Alzheimer's Coordinating Center data. Adults aged 65 years and older newly diagnosed with dementia (n = 2,418) during 2005-2015 were year, age, and sex matched 1:1 with controls. Generalized estimating equation models weighted for missingness and adjusted for 15 participant characteristics were fit.
Results: Among participants with dementia, number of medications reported 1-year prediagnosis was 8% lower than at diagnosis year (p < .0001) and 11% higher 1-year postdiagnosis compared with year of diagnosis (p < .0001). Among participants with dementia, the odds of PIM exposure, assessed using the 2015 Beers Criteria, was 17% lower 1-year prediagnosis (p < .0001) and 17% higher 1-year postdiagnosis (p = .006) compared with year of diagnosis. Among controls, there were approximately 6% more medications reported between consecutive years (p < .0001 each comparison) and the odds of PIM exposure increased 11% between consecutive years (p = .006 and p = .047). At each annual follow-up, participants with dementia had lower odds of PIM exposure than their controls (prediagnosis p < .0001, at diagnosis p = .0007, postdiagnosis p = .03, respectively). There were no differences in exposure to anticholinergic medications. Conclusions: Number of medications and PIM use increased annually for participants with and without dementia. Persistent challenge of increasing PIM use in this group of older adults is of major concern and warrants interventions to minimize such prescribing.

Entities:  

Mesh:

Year:  2018        PMID: 29684111      PMCID: PMC6454446          DOI: 10.1093/gerona/gly078

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  29 in total

1.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

2.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

3.  Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons.

Authors:  Marjaana Koponen; Anna-Maija Tolppanen; Heidi Taipale; Antti Tanskanen; Jari Tiihonen; Kristina Johnell; Johan Fastbom; Riitta Ahonen; Sirpa Hartikainen
Journal:  Br J Psychiatry       Date:  2015-10-08       Impact factor: 9.319

4.  The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.

Authors:  Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

5.  Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review.

Authors:  Mitchell R Redston; Sarah N Hilmer; Andrew J McLachlan; Alexander J Clough; Danijela Gnjidic
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout.

Authors:  George O Agogo; Christine M Ramsey; Danijela Gnjidic; Daniela C Moga; Heather Allore
Journal:  Int Psychogeriatr       Date:  2018-04-18       Impact factor: 3.878

7.  Use of medications of questionable benefit in advanced dementia.

Authors:  Jennifer Tjia; Becky A Briesacher; Daniel Peterson; Qin Liu; Susan E Andrade; Susan L Mitchell
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

8.  Potentially inappropriate medication among people with dementia in eight European countries.

Authors:  Anna Renom-Guiteras; Petra A Thürmann; Ramón Miralles; Renate Klaaßen-Mielke; Ulrich Thiem; Astrid Stephan; Michel H C Bleijlevens; David Jolley; Helena Leino-Kilpi; Ingalill Rahm Hallberg; Kai Saks; Maria Soto-Martin; Adelaida Zabalegui; Gabriele Meyer
Journal:  Age Ageing       Date:  2018-01-01       Impact factor: 10.668

9.  Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study.

Authors:  Danijela Gnjidic; Sarah N Hilmer; Sirpa Hartikainen; Anna-Maija Tolppanen; Heidi Taipale; Marjaana Koponen; J Simon Bell
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

10.  Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis.

Authors:  Christine M Ramsey; Danijela Gnjidic; George O Agogo; Heather Allore; Daniela Moga
Journal:  Alzheimers Dement (N Y)       Date:  2017-11-26
View more
  9 in total

1.  Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease.

Authors:  Danielle S Abraham; Thanh Phuong Pham Nguyen; Sean Hennessy; Daniel Weintraub; Shelly L Gray; Dawei Xie; Allison W Willis
Journal:  Age Ageing       Date:  2020-08-24       Impact factor: 10.668

2.  One-year persistence of potentially inappropriate medication use in older adults: A population-based study.

Authors:  Barbara Roux; Caroline Sirois; Marc Simard; Marie-Eve Gagnon; Marie-Laure Laroche
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

3.  Potentially Inappropriate Medications Pre- and Post-Diagnosis of Major Neurocognitive Disorders Among Older People in Sweden: A Register-Based, 6-Year Longitudinal Study.

Authors:  Eva Sönnerstam; Maria Gustafsson; Hugo Lövheim; Maria Sjölander
Journal:  Drugs Aging       Date:  2022-06-03       Impact factor: 4.271

4.  Anticholinergic medicines use among older adults before and after initiating dementia medicines.

Authors:  Sujita W Narayan; Sallie-Anne Pearson; Melisa Litchfield; David G Le Couteur; Nicholas Buckley; Andrew J McLachlan; Helga Zoega
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

5.  Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia.

Authors:  T Möllers; L Perna; H Stocker; P Ihle; I Schubert; B Schöttker; L Frölich; J Bauer; H Brenner
Journal:  Epidemiol Psychiatr Sci       Date:  2019-11-14       Impact factor: 6.892

6.  Medications causing potential cognitive impairment are common in nursing home dementia units - A cross-sectional study.

Authors:  Jenny Hansen Kristensson; Iris Zahirovic; Elisabet Londos; Sara Modig
Journal:  Explor Res Clin Soc Pharm       Date:  2021-08-05

7.  An investigation of new medications initiation during ambulatory care visits in patients with dementia.

Authors:  Alexandra Wallem; Ashley I Martinez; Lauren Vickers; Michael Singleton; Daniela C Moga
Journal:  Explor Res Clin Soc Pharm       Date:  2021-08-08

8.  Polypharmacy among older adults with dementia compared with those without dementia in the United States.

Authors:  Matthew E Growdon; Siqi Gan; Kristine Yaffe; Michael A Steinman
Journal:  J Am Geriatr Soc       Date:  2021-06-08       Impact factor: 7.538

Review 9.  Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?

Authors:  L P Dantas; A R C C Forte; B C Lima; C N S Sousa; E C Vasconcelos; P H C Lessa; R F Vieira; M C A Patrocínio; S M M Vasconcelos
Journal:  Braz J Med Biol Res       Date:  2022-01-25       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.